THE VENTRICULAR ECOTIC QS INTERVAL (VEQSI): DIAGNOSIS OF ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY (ARVC)

doi:10.1136/heartjnl-2012-301877b.68

Introduction A gold standard test for arrhythmogenic right ventricular cardiomyopathy (ARVC) does not exist and diagnosis relies on meeting Task Force criteria. Sudden death remains the ultimate cardiomyopathy (ARVC) does not exist and diagnosis relies on meeting Task Force criteria. Sudden death remains the ultimate disease. We evaluated the significance of VEQSI in patients with ARVC.

Methods We selected 3 cohorts for 12 lead 24-h Holter monitoring: 51 normal controls (41.7±14.8 years, 55% male); 27 patients with definite ARVC by Task Force criteria (46.4±13.1 years; 70% male); 10 patients with borderline ARVC and a confirmed pathogenic mutation and/or definitely affected first degree relative (34.6±15.0 years; 50% male). All ventricular ectopics (VE) were reviewed and VEQSI was measured for each VE morphology. The longest VE duration was recorded as VEQSI max.

Results VEQSI max was significantly longer in definite ARVC compared with borderline ARVC and normal controls (208.8±18.6 ms, 183.7±12.9 ms and 155.0±14.4 ms respectively; p<0.001). VEQSI max was also significantly longer in borderline ARVC compared with normal controls (p=0.002). When the upper normal limit for VEQSI max was defined as 170 ms there was 97% sensitivity and 93% specificity for diagnosis of ARVC, including 9/10 correct diagnoses in the borderline ARVC group.

Conclusion Maximal VEQSI duration is significantly longer in definite ARVC compared with normal controls, and intermediate in ARVC patients with early disease. VEQSI max >170 ms has high sensitivity and specificity for the diagnosis of ARVC and may be particularly useful in borderline disease.

SYSTEMATIC REVIEW OF 1142 ADMISSIONS WITH ACUTE HEART FAILURE REVEALS HIGH FREQUENCY OF TRANSTHYRETIN V122I CARDIAC AMYLOIDOSIS IN AFRO-CARIBBEAN PATIENTS

doi:10.1136/heartjnl-2012-301877b.69

Abstract 069 Figure 1 Kaplan–Meier curves for all patients (n=1142) demonstrating significantly inferior survival in cardiac amyloidosis compared to non-amyloid cardiomyopathy (p<0.01). Kaplan–Meier curves in Afro-Caribbean patients (n=170) demonstrating no significant difference in survival between ischaemic cardiomyopathy and ATTR V122I (p=0.54).
Abstract 069 Table 1

<table>
<thead>
<tr>
<th>Black ethnicity data</th>
<th>Afro-Caribbean patients N=170</th>
<th>All other patients N=972</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>71 (53–77)</td>
<td>73 (63–81)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Male gender</td>
<td>110 (64.7%)</td>
<td>652 (67.1%)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Ischaemic cardiomyopathy</td>
<td>22 (12.9%)</td>
<td>406 (41.8%)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Non-ischaemic (total)</td>
<td>148 (87.1%)</td>
<td>566 (58.2%)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Amyloid (AL and TTR)</td>
<td>27 (15.9%)</td>
<td>21 (2.2%)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>ATTR V122I</td>
<td>17 (10%)</td>
<td>4 (0.4%)</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

Abstract 070 ENZYME REPLACEMENT THERAPY IMPROVES CARDIAC FEATURES OF FABRY DISEASE

doi:10.1136/heartjnl-2012-301877b.70

M Motwani,* S Banypersad, P Woolfson, S Waldek. Salford Royal Hospital NHS Foundation Trust, UK

Introduction Fabry disease (FD) is an X linked deficiency of α-galactosidase A which leads to an accumulation of globotriaosylceramide (GL-3) throughout the body, particularly in the heart, brain and kidneys. Although left ventricular hypertrophy (LVH) in FD can improve with enzyme-replacement therapy (ERT), the response is difficult to predict. Furthermore, the response of other cardiac features such as aortic dilatation and ECG changes are poorly understood.

Methods A local registry of 66 patients with FD was studied. ECG, echocardiogram and Fabry Outcome Survey-Mainz Severity Score (FOS-MSSI) data were compared between baseline and after long-term ERT (median 36 months).

Results In patients with LVH (n=42), left ventricular mass index (LVMI), maximal wall thickness (MWT), left ventricular end-diastolic diameter (LVEDD) and ejection fraction (EF) were all seen to improve after ERT (LVMI: 135±13 vs 135±13 g/m², MWT: 17±6 vs 16±5 mm, LVEDD: 55±6 vs 54±6 mm; EF: 62±5 vs 64±3%; p<0.05) (Abstract 070 figure 1). In the entire patient group, PQ interval and P wave duration significantly increased with ERT (PQ: 131±15 vs 144±15 ms; P: 76±5 vs 90±6 ms; p values <0.001); QTc interval significantly decreased (418±18 vs 410±15 ms; p<0.001); and median FOS-MSSI score fell from 16 to 14 (p<0.001) (Abstract 070 figure 2). On logistic-regression analysis, none of the recorded baseline features (age, gender, LVMI, MWT, LVEDD, aortic diameter, PQ, interval, P wave duration, QRS duration, QT interval, Romhilt-Estes score or FOS-MSSI) predicted improvements in LVH or FOS-MSSI with ERT (p>0.05).

Conclusions ERT improved LV morphology and function in patients with LVH but there was no relationship between age, gender, FOS-MSSI or baseline ECG/TTE features and the response. ERT also normalised long QTc intervals, short PQ intervals and short P waves; and reduced disease burden (FOS-MSSI).

Abstract 070 Figure 2 Effect of enzyme replacement (ERT) on the conduction system. There was a significant increase in P wave duration and PQ interval from baseline; there was a significant decrease in QRS width and QTc interval from baseline at the end of follow-up (median 3 years). [Values shown are mean±SD].

Conclusions ERT improved LV morphology and function in patients with LVH but there was no relationship between age, gender, FOS-MSSI or baseline ECG/TTE features and the response. ERT also normalised long QTc intervals, short PQ intervals and short P waves; and reduced disease burden (FOS-MSSI).

Abstract 070 Figure 1 Effect of enzyme replacement therapy (ERT) on LV morphology and function in patients with LVH at baseline. Left ventricular mass index (LVMI), maximal wall thickness (MWT), LV end-diastolic diameter (LVEDD) and ejection fraction all showed significant improvements (all p values <0.05) at the end of follow-up (median 3 years). [Values shown are mean±SD].

Abstract 071 CONCENTRIC HYPERTROPHIC REMODELLING AND SUBENDOCARDIAL DYSFUNCTION IN MITOCHONDRIAL DNA POINT MUTATION CARRIERS

doi:10.1136/heartjnl-2012-301877b.71


Background Cardiomyopathy is an independent predictor of morbidity and early mortality in mitochondrial DNA disease, and